Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. reported that on January 11, 2026 it announced certain preliminary unaudited financial information for the quarter and full year ended December 31, 2025. This information is provided in a press release that is furnished as Exhibit 99.1 to the report, rather than being formally filed, which limits how it is incorporated into other regulatory documents.
The company also disclosed that it will post the investor presentation used at the 2026 J.P. Morgan Healthcare Conference, scheduled for January 12, 2026, on its website under the Investors section. These updates are intended to give the market an early view of recent performance and the materials being shared with investors.
Guardant Health’s Chief People Officer, Terilyn J. Monroe, reported selling common stock in three transactions on January 7, 2026. She sold 6,311 shares at a weighted average price of $111.7521 per share, 3,632 shares at $112.6182 per share, and 88 shares at $113.4397 per share. After these sales, she held 20,990 shares of Guardant Health common stock directly. The prices reported are weighted averages for multiple trades within disclosed price ranges.
Guardant Health, Inc. insider Terilyn J. Monroe has filed a notice to sell 10,031 shares of Guardant Health common stock. The planned sale is to be executed through Charles Schwab & Co., Inc., on NASDAQ, with an indicated aggregate market value of $1,124,200.00 and 126,041,089 shares of Guardant Health common stock shown as outstanding.
The shares to be sold were acquired on 01/01/2026 through equity compensation, including 8,720 shares from a performance stock lapse and 1,311 shares from a restricted stock lapse, both from Guardant Health, Inc. The filing also shows that Monroe previously sold 55,167 Guardant Health shares on 12/01/2025 for gross proceeds of $5,846,164.00.
Guardant Health, Inc. director reports RSU vesting and share acquisition. On 12/17/2025, reporting person Manuel Hidalgo Medina acquired 232 shares of Guardant Health common stock at a price of $0 through the settlement of previously granted restricted stock units, reported with transaction code M.
The restricted stock units were granted on July 17, 2024 and vest over four years, with 25% of the shares vesting on the one-year anniversary of that date and the remaining 75% vesting monthly over the following three years. After this transaction, the reporting person beneficially owns 1,029 shares of common stock directly and 7,193 restricted stock units.
Guardant Health, Inc. director Musa Tariq disclosed a small sale of company stock. On 12/17/2025, the reporting person sold 116 shares of Guardant Health common stock at a price of $101.46 per share. After this transaction, the director beneficially owned 7,993 shares of Guardant Health common stock, held in direct ownership. This filing is a routine insider ownership update and does not describe any additional transactions or derivative securities.
Guardant Health, Inc. director reports routine vesting of restricted stock units. On 12/15/2025, a reporting person who serves as a director of Guardant Health, Inc. (ticker GH) acquired 250 shares of common stock at a price of $0 through the vesting and settlement of previously granted restricted stock units. After this transaction, the director beneficially owned 8,109 shares of common stock directly and 3,748 restricted stock units that remain outstanding.
The restricted stock units were originally granted on March 6, 2023 and vest over four years. According to the vesting schedule, 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting in equal monthly installments over the following three-year period.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported equity compensation activity on December 15, 2025. 1,020 Restricted Stock Units converted into common stock at $0 per share, and 535 common shares were withheld by the company to meet tax withholding obligations at $102.67 per share, as explained in a footnote. After these transactions he directly holds 43,657 shares of Guardant Health common stock.
Guardant Health, Inc. (GH) disclosed an insider equity transaction by its Chief Information Officer, Kumud Kalia. On 12/15/2025, 637 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of restricted stock units. On the same date, 323 shares were disposed of at $102.67 per share, with the company retaining these shares to satisfy tax withholding obligations related to the vesting. After these transactions, the reporting person beneficially owned 22,679 shares of common stock directly, along with 1,275 restricted stock units that remain outstanding and subject to future vesting.
Guardant Health, Inc. reported an insider stock transaction by its Chief Commercial Officer. On December 15, 2025, the officer acquired 1,402 shares of common stock at $0 when a portion of a restricted stock unit (RSU) award vested. On the same date, 594 shares were withheld and disposed of at $102.67 per share to cover tax withholding obligations, as explained in the footnotes.
After these transactions, the officer directly owned 26,795 shares of Guardant Health common stock. The RSU award was originally granted on June 9, 2023; 33% vested on June 15, 2024, and the remaining 67% is scheduled to vest in equal quarterly installments over the following two years. Following the reported transaction, 2,804 restricted stock units remained beneficially owned.
Guardant Health, Inc. Co-Chief Executive Officer and director Helmy Eltoukhy reported open-market sales of company stock. On 12/15/2025, he sold 83,945 shares of common stock at a weighted average price of $103.8012 per share, and an additional 6,620 shares at a weighted average price of $104.0224 per share. Both transactions are coded as sales. Following these trades, he beneficially owns 2,047,143 shares of Guardant Health common stock directly. The prices reflect multiple individual transactions within narrow price ranges, and detailed trade breakdowns are available upon request from the company or the reporting person.